医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New Data from Reach2HD Trial Presented at American Neurological Association Annual Meeting

2016年10月19日 AM12:00
このエントリーをはてなブックマークに追加


 

MELBOURNE, Australia

Prana Biotechnology Ltd (ASX:PBT/NASDAQ:PRAN) is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster1 at the American Neurological Association (ANA) Annual Meeting in Baltimore, United States.

Previously it has been reported that executive function as measured by the Trail Making Test Part B (TMTB) was significantly improved in the Reach2HD trial2. Moreover, as previously announced at the Movement Disorders conference at Berlin this year3, of those patients in Reach2HD that reported cognitive improvement using the Huntington Disease Patient-Reported Outcome of Problems, or ‘HD-PROP’ assessment, 90% had received Prana PBT2 treatment.

This new analysis being reported today was undertaken to further explore the verbatim patient-reported outcomes captured by the HD-PROP by applied Natural Language Processing (NLP). The poster titled Applying Natural Language Processing (NLP) to Verbatim Patient Reported Outcomes explores natural language processing and memory activity of patients enrolled in the Reach2HD clinical trial and was presented by Professor Ira Shoulson and Dr Karen Anderson and research colleagues at the Georgetown MedStar University (Washington DC).

Using NLP methods to extract relationships and meaning from large text-based resources, such as the HD-PROP verbatim data, word clouds (images composed of words from a text where the size of the word indicates frequency or importance) were derived from the HD-PROP data in the Reach2HD trial at baseline and week 26. The Reach2HD NLP data showed a decrease in “memory” complaints at week 26 in the PBT2 250mg treatment compared with placebo. This improvement in cognitive function using the NLP computer based examination of the patient reported data, supports the positive cognition findings with PBT2 to date from both the HD-PROP assessment and the TMTB rating scale.

Dr Karen Anderson, study principal investigator stated: “The study shows the potential of listening to subjects’ own reports about how a treatment impacts them, rather than relying only on clinician ratings.”

1 ANA Abstract Submission NLP 4.8.16 and NLP Poster

2 Huntington Study Group Reach2HD Investigators (2015). Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: a Phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol.14(1):39-47. Published Online November 14, 2014 http://dx.doi.org/10.1016/S1474-4422(14)70262-5

3 20th Annual International Movement Disorder Society Congress, Berlin 22 June, 2016

View source version on businesswire.com: http://www.businesswire.com/news/home/20161018005693/en/

CONTACT

Investor Relations
Buchan Consulting
Rebecca Wilson,
+61 3 9866 4722
rwilson@buchanwe.com.au
or
Media
Buchan
Consulting
Scott Newstead, +61 3 9866 4722
snewstead@buchanwe.com.au

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease